Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -62.61% is 65% above its 1-year average of -181.47%, near the high end of its 1-year range (-260.33%–-62.61%).
As of the fiscal period ended Tuesday, June 30, 2026. 65.50% above its 12-month average of -181.47%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -62.61%.
RETURN ON EQUITY (ROE)
-62.61%
RETURN ON EQUITY (ROE) AVG TTM
-181.47%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+65.50%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.56%
median of 737 covered companies
CURRENT VS SECTOR MEDIAN
-50.65%
vs the sector median at left
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$103.68M
Return on Equity (ROE)
-62.61%
TTM Avg
-181.47%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.72M
Return on Equity (ROE)
-44.29%
TTM Avg
-31.86%
3Y Avg
-53.29%
5Y Avg
-49.85%
Market Cap
$106.93M
Return on Equity (ROE)
-138.73%
TTM Avg
-151.26%
3Y Avg
-114.36%
5Y Avg
-241.91%
Market Cap
$105.20M
Return on Equity (ROE)
-116.28%
TTM Avg
-71.19%
3Y Avg
-41.66%
5Y Avg
-29.50%
Market Cap
$104.79M
Return on Equity (ROE)
-72.02%
TTM Avg
-67.42%
3Y Avg
-55.49%
5Y Avg
-62.36%
Market Cap
$107.09M
Return on Equity (ROE)
-99.67%
TTM Avg
-40.73%
3Y Avg
98.81%
5Y Avg
13.93%
Market Cap
$107.20M
Return on Equity (ROE)
-87.45%
TTM Avg
455.42%
3Y Avg
120.34%
5Y Avg
63.42%
Market Cap
$107.19M
Return on Equity (ROE)
N/A
TTM Avg
148.53%
3Y Avg
-12.61%
5Y Avg
-408.56%
Market Cap
$103.06M
Return on Equity (ROE)
-34.11%
TTM Avg
-78.33%
3Y Avg
-16.94%
5Y Avg
-8.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $103.68M | -62.61% | -181.47% | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $105.72M | -44.29% | -31.86% | -53.29% | -49.85% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | -138.73% | -151.26% | -114.36% | -241.91% |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | -116.28% | -71.19% | -41.66% | -29.50% |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.79M | -72.02% | -67.42% | -55.49% | -62.36% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | -99.67% | -40.73% | 98.81% | 13.93% |
| Immunic, Inc. (IMUX)vs › | $107.20M | -87.45% | 455.42% | 120.34% | 63.42% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.19M | N/A | 148.53% | -12.61% | -408.56% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | -34.11% | -78.33% | -16.94% | -8.09% |
| The Joint Corp. (JYNT)vs › | $102.21M | 23.96% | -4.38% | -11.56% | 6.84% |
ROE
-62.6%
ROA
-58.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -62.61% |
| 2026-03-31 | -260.33% |
| 2025-12-31 | -196.82% |
| 2025-09-30 | -154.93% |
| 2025-06-30 | -232.65% |
